Paper Details

  1. Home
  2. Paper Details

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.

Author: BellmuntJoaquim, SchmidingerManuela

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Novel agents for treating metastatic renal cell carcinoma have a variety of side effects, many related to their mechanisms of action, such as VEGF inhibition or multiple receptor tyrosine kinase inhibition.
Paper Details　
Original Abstract of the Article :
The plethora of novel agents recently approved for the management of metastatic renal cell carcinoma (RCC) has changed the therapeutic landscape in this disease. The plethora of targets some of these agents inhibit can result in a wide range of side effects. While these novel therapies can be viewed...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ctrv.2010.01.003

データ提供：米国国立医学図書館（NLM）

Navigating the Side Effects of Novel Agents for Metastatic Renal Cell Carcinoma

The treatment landscape for metastatic renal cell carcinoma (RCC) has significantly changed with the advent of novel agents targeting various pathways involved in tumor growth and spread. While these agents offer hope, they come with a complex array of side effects, making it essential to understand their mechanisms of action and manage potential complications.

A Balancing Act: Efficacy and Toxicity

The authors meticulously analyze the side-effect profiles of different agents, highlighting the importance of personalized medicine in RCC treatment. Agents directly inhibiting vascular endothelial growth factor (VEGF), such as bevacizumab, are primarily associated with VEGF-related side effects like proteinuria and hypertension. Conversely, agents targeting multiple receptor tyrosine kinases (RTKs) and mammalian target of rapamycin (mTOR) inhibitors can lead to a broader spectrum of side effects, including diarrhea, skin rash, and metabolic abnormalities.

Understanding the Side Effects for Informed Treatment

This research emphasizes the need for careful consideration of the potential side effects of novel therapies. Patients and their doctors must work together to weigh the benefits of these treatments against the risks.

Dr. Camel's Conclusion

Just as a camel navigates the challenging desert terrain, treating RCC requires careful navigation of the complex landscape of novel agents and their associated side effects. Understanding the mechanisms of action of these drugs is crucial for optimizing treatment outcomes and managing potential complications.

Date :
  1. Date Completed 2010-09-21
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

20163917

DOI: Digital Object Identifier

10.1016/j.ctrv.2010.01.003

Related Literature

Article Analysis
・Side Effects of axitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.